Detalhe da pesquisa
1.
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Eur Heart J
; 44(46): 4878-4889, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806405
2.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Breast Cancer Res Treat
; 195(3): 341-351, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986801
3.
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
Mod Pathol
; 35(3): 396-402, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593966
4.
A phase 2 clinical trialâ¯assessing theâ¯efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Cancer
; 126(4): 850-860, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31747077
5.
Mammographic screening in male patients at high risk for breast cancer: is it worth it?
Breast Cancer Res Treat
; 177(3): 705-711, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280425
6.
Male breast cancer: a disease distinct from female breast cancer.
Breast Cancer Res Treat
; 173(1): 37-48, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30267249
7.
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 111-120, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29744674
8.
The Androgen Receptor: Is It a Promising Target?
Ann Surg Oncol
; 24(10): 2876-2880, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28766215
9.
The microbial flora of taxane therapy-associated nail disease in cancer patients.
J Am Acad Dermatol
; 78(3): 607-609, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29447679
10.
Androgen receptor-positive, triple-negative breast cancer.
Cancer
; 123(10): 1686-1688, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28406524
11.
Spectrum of HIV lymphoma 2009.
Curr Opin Hematol
; 17(4): 362-7, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20442655
12.
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 26(23): 6149-6157, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988969
13.
"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering.
J Oncol Pract
; 15(4): e277-e288, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689492
14.
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
JAMA Netw Open
; 2(11): e1916211, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31774522
15.
Skin necrosis induced by generic enoxaparin.
Am J Hematol
; 88(4): 339, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23450519
16.
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
J Clin Oncol
; 36(9): 884-890, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29373071
17.
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.
Cancer Prev Res (Phila)
; 11(4): 203-214, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453232
18.
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
Clin Cancer Res
; 23(15): 4046-4054, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28280092
19.
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Cancer Prev Res (Phila)
; 10(4): 235-243, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270386
20.
Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers.
J Clin Endocrinol Metab
; 102(5): 1692-1701, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28323914